Voyager Therapeutics, Inc.

www.voyagertherapeutics.com

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

ORION BIOTECHNOLOGY AND PEPTILOGICS ENTER STRATEGIC RESEARCH COLLABORATION TO ENABLE AI-DRIVEN DRUG DISCOVERY AGAINST UNDRUGGED GPCR TARGET

Orion Biotechnology | July 15, 2022

news image

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target. The collaboration will combine the...

Read More

ECOGEN LABORATORIES ANNOUNCES OPERATIONAL UPDATE AMID COVID-19 PANDEMIC

BioSpace | March 20, 2020

news image

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

Read More

Medical

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

news image

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More

Industrial Impact

NIMBUS THERAPEUTICS ANNOUNCES EXPANSION OF ITS IMMUNOLOGY DRUG DISCOVERY PIPELINE

Nimbus Therapeutics | January 08, 2024

news image

Nimbus Therapeutics, LLC a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways. These programs, targeting the salt-inducible kinase (SIK) family and cyclic GMP-AMP synthase (cGAS), represent promising opportunities to leverage Nimbus’ industry-leading computational and structure-...

Read More
news image

Industrial Impact

ORION BIOTECHNOLOGY AND PEPTILOGICS ENTER STRATEGIC RESEARCH COLLABORATION TO ENABLE AI-DRIVEN DRUG DISCOVERY AGAINST UNDRUGGED GPCR TARGET

Orion Biotechnology | July 15, 2022

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target. The collaboration will combine the...

Read More
news image

ECOGEN LABORATORIES ANNOUNCES OPERATIONAL UPDATE AMID COVID-19 PANDEMIC

BioSpace | March 20, 2020

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

Read More
news image

Medical

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More
news image

Industrial Impact

NIMBUS THERAPEUTICS ANNOUNCES EXPANSION OF ITS IMMUNOLOGY DRUG DISCOVERY PIPELINE

Nimbus Therapeutics | January 08, 2024

Nimbus Therapeutics, LLC a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways. These programs, targeting the salt-inducible kinase (SIK) family and cyclic GMP-AMP synthase (cGAS), represent promising opportunities to leverage Nimbus’ industry-leading computational and structure-...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us